AlphaCentric Advisors LLC Sells 9,500 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

AlphaCentric Advisors LLC decreased its holdings in BeiGene, Ltd. (NASDAQ:BGNE) by 63.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,500 shares of the company’s stock after selling 9,500 shares during the period. AlphaCentric Advisors LLC’s holdings in BeiGene were worth $1,235,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Janney Montgomery Scott LLC increased its holdings in shares of BeiGene by 63.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 2,280 shares of the company’s stock worth $357,000 after buying an additional 887 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in BeiGene during the 1st quarter valued at about $209,000. AIA Group Ltd increased its stake in BeiGene by 38.9% during the 1st quarter. AIA Group Ltd now owns 18,497 shares of the company’s stock valued at $2,893,000 after purchasing an additional 5,181 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in shares of BeiGene by 9.1% in the first quarter. Oppenheimer Asset Management Inc. now owns 18,124 shares of the company’s stock worth $2,834,000 after acquiring an additional 1,507 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of BeiGene in the first quarter worth approximately $50,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Insider Buying and Selling

In other BeiGene news, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Titus B. Ball sold 137 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Xiaobin Wu sold 500 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $200.00, for a total value of $100,000.00. Following the completion of the sale, the chief operating officer now owns 4,500 shares in the company, valued at $900,000. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,070 shares of company stock valued at $4,901,050. 7.43% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BGNE. Bank of America reduced their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. JMP Securities initiated coverage on shares of BeiGene in a research report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. Finally, Citigroup boosted their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, BeiGene presently has an average rating of “Moderate Buy” and a consensus target price of $246.21.

BeiGene Trading Up 1.5 %

Shares of NASDAQ:BGNE opened at $207.25 on Tuesday. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $248.16. The company’s 50 day moving average is $211.76 and its 200 day moving average is $178.98.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The business’s revenue was up 56.1% on a year-over-year basis. During the same quarter last year, the firm posted ($3.64) EPS. Analysts expect that BeiGene, Ltd. will post -5 EPS for the current fiscal year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.